{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:51:52Z","timestamp":1782921112824,"version":"3.54.5"},"reference-count":37,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Propylthiouracil (PTU) use has decreased due to adverse events (AEs), but it is still needed for patients who cannot tolerate thiamazole.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of the PTU protocol between high-dose monotherapy and low-dose combination therapy with potassium iodide (KI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a retrospective observational study including patients who were newly diagnosed with Graves disease (GD) and received PTU as initial therapy between January 2005 and October 2024. Patients who received an initial dose of 300\u2005mg (high-dose group) and those who received 150\u2005mg of PTU combined with 50\u2005mg of KI (low-dose group) were included. The propensity-score matching method was employed to adjust for confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1171 patients (high-dose: low-dose = 1133: 38, all female) with a median age of 32 (interquartile range [IQR]: 28-36)\u2005years were included. Median levels of free-thyroxine (FT4) and thyroid-stimulating hormone receptor antibody were 4.97 (IQR: 3.67-7.31) ng\/dL, 12.4 (IQR: 6.4-26.8) IU\/L. Adverse events occurred in 294 patients (high-dose: low-dose = 289:5). Free-thyroxine levels were significantly lower at Week 2 in the low-dose group than in the high-dose group (P = .014), but the difference disappeared afterwards. The prevalence of inadequate efficacy with the initial dose was significantly higher in the low-dose group (12.8% vs 35.5%, P = .002).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite a lower rate of efficacy from the initial dose, the low-dose protocol was effective in controlling hyperthyroidism with up-titration in young women with GD, with the potential for fewer AEs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jendso\/bvag137","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:41:24Z","timestamp":1781955684000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of propylthiouracil protocols: high-dose monotherapy vs combination of low-dose with iodine"],"prefix":"10.1210","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2877-6647","authenticated-orcid":false,"given":"Nami","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Ito Hospital , Shibuya, Tokyo 150-0001 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7340-8603","authenticated-orcid":false,"given":"Jaeduk Yoshimura","family":"Noh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ito Hospital , Shibuya, Tokyo 150-0001 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2297-5004","authenticated-orcid":false,"given":"Natsuko","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ito Hospital , Shibuya, Tokyo 150-0001 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1323-4722","authenticated-orcid":false,"given":"Ai","family":"Yoshihara","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ito Hospital , Shibuya, Tokyo 150-0001 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6815-5891","authenticated-orcid":false,"given":"Miho","family":"Fukushita","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ito Hospital , Shibuya, Tokyo 150-0001 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7265-6787","authenticated-orcid":false,"given":"Masako","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ito Hospital , Shibuya, Tokyo 150-0001 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0170-2804","authenticated-orcid":false,"given":"Masakazu","family":"Koshibu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ito Hospital , Shibuya, Tokyo 150-0001 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7106-6688","authenticated-orcid":false,"given":"Miki","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ito Hospital , Shibuya, Tokyo 150-0001 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7417-2751","authenticated-orcid":false,"given":"Aiko","family":"Kitao","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ito Hospital , Shibuya, Tokyo 150-0001 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9692-9871","authenticated-orcid":false,"given":"Kiminori","family":"Sugino","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital , Shibuya, Tokyo 150-0001 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2341-3620","authenticated-orcid":false,"given":"Koichi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital , Shibuya, Tokyo 150-0001 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"11","key":"2026070107315998600_bvag137-B1","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1210\/clinem\/dgae222","article-title":"A 2023 International Survey of clinical practice patterns in the management of Graves disease: a decade of change","volume":"109","author":"Villagelin","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026070107315998600_bvag137-B2","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"issue":"4","key":"2026070107315998600_bvag137-B3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000490384","article-title":"2018 European Thyroid Association Guideline for the management of Graves\u2019 hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur Thyroid J"},{"issue":"9","key":"2026070107315998600_bvag137-B4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra042972","article-title":"Antithyroid drugs","volume":"352","author":"Cooper","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"2026070107315998600_bvag137-B5","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1089\/thy.2019.0045","article-title":"Analysis of antithyroid drug-induced severe liver injury in 18,558 newly diagnosed patients with Graves\u2019 disease in Japan","volume":"29","author":"Suzuki","year":"2019","journal-title":"Thyroid"},{"issue":"7","key":"2026070107315998600_bvag137-B6","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1507\/endocrj.EJ24-0135","article-title":"Dose-dependent incidence of agranulocytosis in patients treated with methimazole and propylthiouracil","volume":"71","author":"Yoshimura Noh","year":"2024","journal-title":"Endocr J"},{"issue":"1","key":"2026070107315998600_bvag137-B7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/thy.2014.0084","article-title":"Comparison of efficacy and adverse effects between methimazole 15\u2005mg + inorganic iodine 38\u2005mg\/day and methimazole 30\u2005mg\/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism","volume":"25","author":"Sato","year":"2015","journal-title":"Thyroid"},{"key":"2026070107315998600_bvag137-B8","volume-title":"Guideline for the Treatment of Graves' Disease in Japan","author":"Japan Thyroid Association","year":"2019"},{"issue":"4","key":"2026070107315998600_bvag137-B9","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1210\/jc.2015-4274","article-title":"Antithyroid drug side effects in the population and in pregnancy","volume":"101","author":"Andersen","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026070107315998600_bvag137-B10","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1210\/jc.2013-2569","article-title":"Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30\u2005years in Japan","volume":"98","author":"Nakamura","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070107315998600_bvag137-B11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1507\/endocrj.EJ25-0274","article-title":"Thyroid volume reduction in patients with thyroid stimulation-blocking antibody who transitioned from Graves' hyperthyroidism to hypothyroidism: a single-center retrospective study","volume":"73","author":"Hirose","year":"2026","journal-title":"Endocr J"},{"key":"2026070107315998600_bvag137-B12","unstructured":"Suzuki N, Noh JY, Watanabe N, et al \u00a02026. Supplementary Data from: Efficacy and safety of propylthiouracil protocols: High-dose monotherapy vs. combination of low-dose with iodine. The Dataverse Network. Date of deposit Deposited 2 June 2026. 10.7910\/DVN\/KE3GX9."},{"issue":"1","key":"2026070107315998600_bvag137-B13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1507\/endocrj.EJ24-0186","article-title":"A narrative review of long-term inorganic iodine monotherapy for Graves' disease with a historical relationship between iodine and thyroid","volume":"72","author":"Watanabe","year":"2025","journal-title":"Endocr J"},{"issue":"3","key":"2026070107315998600_bvag137-B14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/thy.2023.0068","article-title":"Iodine in the therapy of Graves\u2019 disease: a century after Henry S. Plummer","volume":"33","author":"Kopp","year":"2023","journal-title":"Thyroid. Mar"},{"issue":"1","key":"2026070107315998600_bvag137-B15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1172\/JCI106225","article-title":"Inhibition by iodine of the release of thyroxine from the thyroid glands of patients with thyrotoxicosis","volume":"49","author":"Wartofsky","year":"1970","journal-title":"J Clin Invest"},{"issue":"2","key":"2026070107315998600_bvag137-B16","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0021-9258(18)57335-X","article-title":"Plasma inorganic iodide as a homeostatic regulator of thyroid function","volume":"174","author":"Wolff","year":"1948","journal-title":"J Biol Chem"},{"issue":"3","key":"2026070107315998600_bvag137-B17","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1089\/thy.2022.0496","article-title":"The effect of long-term inorganic iodine on intrathyroidal iodothyronine content and gene expression in mice with Graves\u2019 hyperthyroidism","volume":"33","author":"Uchida","year":"2023","journal-title":"Thyroid"},{"issue":"4","key":"2026070107315998600_bvag137-B18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1210\/jcem-30-4-469","article-title":"Effect of iodide on thyroidal iodine turnover in hyperthyroid subjects","volume":"30","author":"Nagataki","year":"1970","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026070107315998600_bvag137-B19","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/0003-4819-56-4-577","article-title":"The effect of small doses of stable iodine in patients with hyperthyroidism","volume":"56","author":"Volpe","year":"1962","journal-title":"Ann Intern Med"},{"issue":"3","key":"2026070107315998600_bvag137-B20","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1172\/JCI101828","article-title":"Minimum dosage of Thiourea, given together with iodine medication, necessary for the production and maintenance of a remission in hyperthyroidism","volume":"26","author":"Winkler","year":"1947","journal-title":"J Clin Invest"},{"key":"2026070107315998600_bvag137-B21","first-page":"399","article-title":"Quantitative studies of iodine metabolism in iodide-treated thyrotoxicosis","volume":"27","author":"Harden","year":"1964","journal-title":"Clin Sci"},{"issue":"12","key":"2026070107315998600_bvag137-B22","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.4158\/EP-2017-0044","article-title":"Relationship between the effectiveness of inorganic iodine and the severity of Graves thyrotoxicosis: a retrospective study","volume":"23","author":"Honda","year":"2017","journal-title":"Endocr Pract"},{"issue":"2","key":"2026070107315998600_bvag137-B23","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s12020-014-0171-8","article-title":"Therapeutic effectiveness of potassium iodine in drug-naive patients with Graves\u2019 disease: a single-center experience","volume":"47","author":"Uchida","year":"2014","journal-title":"Endocrine"},{"issue":"11","key":"2026070107315998600_bvag137-B24","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1210\/jc.2013-4466","article-title":"Remission after potassium iodide therapy in patients with Graves\u2019 hyperthyroidism exhibiting thionamide-associated side effects","volume":"99","author":"Okamura","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026070107315998600_bvag137-B25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1507\/endocrj.EJ19-0379","article-title":"Therapeutic efficacy and limitations of potassium iodide for patients newly diagnosed with Graves\u2019 disease","volume":"67","author":"Suzuki","year":"2020","journal-title":"Endocr J"},{"issue":"7","key":"2026070107315998600_bvag137-B26","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1507\/endocrj.EJ20-0016","article-title":"Clinical experience of treating Graves' hyperthyroidism complicated with malignancy\u2014the possible role of potassium iodide for avoiding the risk of thionamide-associated neutropenia","volume":"67","author":"Okamura","year":"2020","journal-title":"Endocr J"},{"issue":"6","key":"2026070107315998600_bvag137-B27","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1507\/endocrj.EJ24-0575","article-title":"Influence of therapeutic inorganic iodine on long-term prognosis of Graves' disease: a multicenter prospective observational study","volume":"72","author":"Takizawa","year":"2025","journal-title":"Endocr J"},{"issue":"6","key":"2026070107315998600_bvag137-B28","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-24-0085","article-title":"Graves' hyperthyroidism treated with potassium iodide: early response and after 2\u2005years of follow-up","volume":"13","author":"Fujikawa","year":"2024","journal-title":"Eur Thyroid J"},{"key":"2026070107315998600_bvag137-B29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.aed.2025.10.015","article-title":"Iodine for the outpatient management of Graves' disease: a case series of 7 patients","volume":"13","author":"Magvanjav","year":"2026","journal-title":"AACE Endocrinol Diabetes"},{"issue":"6","key":"2026070107315998600_bvag137-B30","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1210\/endrev\/bnae019","article-title":"Risks of iodine excess","volume":"45","author":"Sohn","year":"2024","journal-title":"Endocr Rev"},{"issue":"4","key":"2026070107315998600_bvag137-B31","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1530\/EJE-17-0314","article-title":"Birth defects after use of antithyroid drugs in early pregnancy: a Swedish nationwide study","volume":"177","author":"Andersen","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2026070107315998600_bvag137-B32","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1210\/jc.2019-01343","article-title":"Maternal thyroid function, use of antithyroid drugs in early pregnancy, and birth defects","volume":"104","author":"Andersen","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026070107315998600_bvag137-B33","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1210\/jc.2011-2860","article-title":"Treatment of graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation","volume":"97","author":"Yoshihara","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026070107315998600_bvag137-B34","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa204","article-title":"Exposure to propylthiouracil in the first trimester of pregnancy and birth defects: a study at a single institution","volume":"5","author":"Yoshihara","year":"2021","journal-title":"J Endocr Soc"},{"issue":"10","key":"2026070107315998600_bvag137-B35","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1089\/thy.2014.0581","article-title":"Substituting potassium iodide for methimazole as the treatment for Graves' disease during the first trimester may reduce the incidence of congenital anomalies: a retrospective study at a single medical institution in Japan","volume":"25","author":"Yoshihara","year":"2015","journal-title":"Thyroid"},{"issue":"1","key":"2026070107315998600_bvag137-B36","doi-asserted-by":"crossref","DOI":"10.1186\/s13044-026-00291-w","article-title":"Iodide for the management of Graves' disease in pregnancy","volume":"19","author":"Yoshihara","year":"2026","journal-title":"Thyroid Res"},{"issue":"3","key":"2026070107315998600_bvag137-B37","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1507\/endocrj.K08E-240","article-title":"Preoperative administration of excess iodide increases thyroid volume of patients with Graves' disease","volume":"56","author":"Yabuta","year":"2009","journal-title":"Endocr J"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvag137\/68584307\/bvag137.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/7\/bvag137\/68584307\/bvag137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/7\/bvag137\/68584307\/bvag137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:25:28Z","timestamp":1782919528000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvag137\/8713833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,3]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvag137","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,3]]},"article-number":"bvag137"}}